Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Wendy Callen

Physician Assistant, Surgical Amherst, NY Physician Assistant

NPI 1609851401 CMS profile 1388859

3980 Sheridan Dr, Suite 200, Amherst, NY 14226

Open in the dashboard

General payments

$15,251

824 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Wendy Callen of Amherst, NY is reported in the CMS Open Payments database as having received $15,251 across 824 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant, Surgical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $492 18
2024 General $2,874 106
2023 General $5,191 246
2022 General $3,975 280
2021 General $2,720 174

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Wendy Callen
  • Physician Assistant, Surgical median
  • Middle half of Physician Assistant, Surgical
  • National median

In program year 2025, general payments to Wendy Callen were reported at $492. Among 8,152 Physician Assistant, Surgical profiles paid that year, the median was $146 and the middle half received between $51 and $385.

Show as a table
Year Wendy Callen Physician Assistant, Surgical median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $2,720 $111 $36–$285 $132
2022 $3,975 $126 $44–$350 $149
2023 $5,191 $137 $47–$355 $160
2024 $2,874 $146 $49–$384 $164
2025 $492 $146 $51–$385 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Biogen, Inc. $1,325 125 payments
  2. US WorldMeds, LLC $1,299 40 payments
  3. Novartis Pharmaceuticals Corporation $1,183 77 payments
  4. AbbVie, Inc. $1,166 54 payments
  5. EMD Serono, Inc. $1,073 12 payments
  6. Genentech USA, Inc. $792 36 payments
  7. Teva Pharmaceuticals USA, Inc. $772 41 payments
  8. Horizon Therapeutics plc $650 29 payments
  9. Argenx US, Inc. $530 10 payments
  10. UCB, Inc. $472 21 payments
  11. Other $5,991 379 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $14,640 800 payments
  2. Education $362 23 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $250 1 payment
Products named General payments · program years 2021–2025
  1. Gocovri $1,042 26 payments
  2. VUMERITY $952 87 payments
  3. OCREVUS $775 33 payments
  4. KESIMPTA Neurology $712 43 payments
  5. UPLIZNA $617 27 payments
  6. PLEGRIDY $522 60 payments
  7. VYVGART $510 9 payments
  8. UBRELVY $469 23 payments
  9. TYSABRI $449 33 payments
  10. KESIMPTA Neuroscience $440 32 payments
  11. Other $10,386 634 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 70 drugs

Part D claims

3,729

Median for Physician Assistant: 241

Drug cost

$1,986,273

Median for Physician Assistant: $4,110

Branded share of claims

24%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Avonex Pen (4 Pack) Interferon Beta-1a Brand 41 $332,855
Gammagard Liquid Immun Glob G(Igg)/Gly/Iga Ov50 Brand 40 $291,974
Kesimpta Pen Ofatumumab Brand 25 $251,136
Copaxone Glatiramer Acetate Brand 36 $218,892
Avonex (4 Pack) Interferon Beta-1a Brand 23 $199,205
Gamunex-C Immune Globul G/Gly/Iga Avg 46 Brand 38 $195,126
Zeposia Ozanimod Hydrochloride Brand 20 $175,272
Glatopa Glatiramer Acetate Brand 13 $59,293
Glatiramer Acetate Generic 18 $51,149
Dimethyl Fumarate Generic 32 $48,052

The 10 drugs with the highest cost, of 70 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 9 billing codes

Paid by Medicare

$10,238

Medicare's payments for the services billed

Medicare patients

147

Average age 68

Services billed

210

78 women, 69 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 67%
Arthritis 48%
Chronic kidney disease 33%
Depression 31%
Diabetes 24%
Ischemic heart disease 20%
Cancer 15%
COPD 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 35 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Gocovri
  • US WorldMeds, LLC $850
$850 — —
KESIMPTA
  • Novartis Pharmaceuticals Corporation $231
$231 25 —
Nayzilam
  • UCB, Inc. $94
$94 — —
UBRELVY
  • AbbVie, Inc. $88
$88 — —
INGREZZA
  • Neurocrine Biosciences, Inc. $82
$82 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 35 with Patron

Records

824 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Surgical in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record